Physician

Scott Andrew Sarrels, M.D.

According to 2025 Medicare claims, Scott Sarrels, M.D. (NPI: 1588981872) practices gastroenterology in the Dothan, AL market, with the plurality of this provider's patient population coming from Houston, AL. This provider's primary affiliated billing organization is GUT PC (NPI: 1073566006; TIN: 20-2904686) and primary practice location at 36305-1156. Sarrels is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Sarrels' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 850 traditional Medicare patients, billed 20,130 HCPCS/CPT codes, and received $444,342 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,151 prescription claims across 869 beneficiaries totaling $3,712,172 in drug costs, led by Stelara (Ustekinumab). 2018 DME data shows 47 claims. Open Payments data shows 80 records totaling $27,283. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $88,808 to $444,342. Similarly, Part D prescription costs have moved sharply higher in recent years, from $259,163 to $3,712,172. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	542	1,180	$88,808
2017	1,240	11,866	$235,759
2018	1,106	43,624	$380,741
2019	1,163	16,452	$385,715
2020	1,121	17,624	$348,088
2021	1,020	21,750	$432,790
2022	895	16,096	$334,162
2023	884	18,138	$377,141
2024	850	20,130	$444,342

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	250	776	$259,163
2016	244	704	$57,607
2017	341	1,078	$104,000
2018	455	1,531	$371,092
2019	553	2,043	$607,693
2020	647	3,099	$1,295,706
2021	764	3,582	$1,939,724
2022	785	3,930	$2,400,193
2023	829	4,139	$3,295,124
2024	869	4,151	$3,712,172

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	43	$648
2016	28	43	$604
2017	N/R	11	$725
2018	N/R	47	$4,753
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	163	163	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	313	404	$85
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	189	201	$51
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	173	1,091	$46
99439	Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month	170	1,838	$35

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	38	2,100	$1,017,921
Epclusa	Sofosbuvir/Velpatasvir	11	308	$270,387
Creon	Lipase/Protease/Amylase	93	2,796	$250,078
Dupixent Pen	Dupilumab	28	784	$206,016
Humira(Cf) Pen	Adalimumab	27	756	$181,701

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,306	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	21	$25,977	Bausch Health US, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott Andrew Sarrels, M.D.?

Tedicare shows public-source Medicare data for Scott Andrew Sarrels, M.D. (NPI 1588981872), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott Andrew Sarrels, M.D. have ACO affiliation data?

Scott Andrew Sarrels, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Scott Andrew Sarrels, M.D.?

Scott Andrew Sarrels, M.D. is linked to GUT PC (billing NPI 1073566006) in the available physician profile data.

Does Scott Andrew Sarrels, M.D. have Open Payments data?

Scott Andrew Sarrels, M.D. has 80 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.